{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:48:33Z","timestamp":1783183713245,"version":"3.54.6"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Det Frie Forskningsrad Sundhed og Sygdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005747","name":"AP Moller Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.metabol.2024.155915","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T01:34:19Z","timestamp":1713231259000},"page":"155915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms"],"prefix":"10.1016","volume":"156","author":[{"given":"Michael M.","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida M.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Heeb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Winther-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha A.S.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus D.","family":"Nybing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik H.","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"H\u00f8gh-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael P.","family":"Boesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Vinholt","family":"Schi\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen B.","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Rungby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai J.","family":"Wewer Albrechtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.155915_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.metabol.2024.155915_bb0010","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiol Rev"},{"issue":"21","key":"10.1016\/j.metabol.2024.155915_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.metabol.2024.155915_bb0025","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2024.155915_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.molmet.2015.06.001","article-title":"Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans","volume":"4","author":"Hansen","year":"2015","journal-title":"Mol Metab"},{"issue":"12","key":"10.1016\/j.metabol.2024.155915_bb0035","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","article-title":"Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss","volume":"1","author":"Day","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.metabol.2024.155915_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1037948","article-title":"GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans","volume":"13","author":"Plomgaard","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7795","key":"10.1016\/j.metabol.2024.155915_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","article-title":"FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver","volume":"23","author":"von Holstein-Rathlou","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.155915_bb0060","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","article-title":"FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans","volume":"25","author":"Soberg","year":"2017","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.metabol.2024.155915_bb0065","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.metabol.2024.155915_bb0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat Med"},{"issue":"7675","key":"10.1016\/j.metabol.2024.155915_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.metabol.2024.155915_bb0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.metabol.2024.155915_bb0085","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.metabol.2024.155915_bb0090","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.metabol.2024.155915_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"issue":"10165","key":"10.1016\/j.metabol.2024.155915_bb0110","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.metabol.2024.155915_bb0115","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.metabol.2024.155915_bb0120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cmet.2023.06.016","article-title":"GDF15 increases insulin action in the liver and adipose tissue via a beta-adrenergic receptor-mediated mechanism","volume":"35","author":"Sjoberg","year":"2023","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.metabol.2024.155915_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034868","article-title":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets","volume":"7","author":"Macia","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmet.2022.12.011","article-title":"Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist","volume":"35","author":"Benichou","year":"2023","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.metabol.2024.155915_bb0135","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41387-022-00187-2","article-title":"Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity","volume":"12","author":"Galuppo","year":"2022","journal-title":"Nutr Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1373\/clinchem.2010.153726","article-title":"The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients","volume":"57","author":"Vila","year":"2011","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2007-985148","article-title":"Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus","volume":"116","author":"Chen","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2024.155915_bb0160","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00125-012-2803-y","article-title":"Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?","volume":"56","author":"Arafat","year":"2013","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.metabol.2024.155915_bb0165","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1210\/jc.2017-01257","article-title":"FGF21 is an insulin-dependent postprandial hormone in adult humans","volume":"102","author":"Samms","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2024.155915_bb0170","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s00125-017-4373-5","article-title":"Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes","volume":"60","author":"Kruse","year":"2017","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.metabol.2024.155915_bb0175","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2337\/db09-0713","article-title":"Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia","volume":"58","author":"Hojman","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2024.155915_bb0180","article-title":"Hepatic glucose production, ureagenesis, and lipolysis quantified using the perfused mouse liver model","volume":"200","author":"Winther-Sorensen","year":"2023","journal-title":"J Vis Exp"},{"issue":"6","key":"10.1016\/j.metabol.2024.155915_bb0185","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"L. European Association for the Study of the","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155915_bb0190","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155915_bb0195","article-title":"Development of a glucagon sensitivity test in humans: pilot data and the GLUSENTIC study protocol","volume":"161","author":"Kjeldsen","year":"2022","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.metabol.2024.155915_bb0200","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/db22-0313","article-title":"Impaired glucagon-mediated suppression of VLDL-triglyceride secretion in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD)","volume":"71","author":"Heeboll","year":"2022","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.metabol.2024.155915_bb0205","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.metabol.2024.155915_bb0210","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.155915_bb0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","article-title":"FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest","volume":"11","author":"Soberg","year":"2018","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17574-w","article-title":"GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury","volume":"7","author":"Chung","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/00365513.2021.2016943","article-title":"On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA","volume":"82","author":"Wewer Albrechtsen","year":"2022","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.metabol.2024.155915_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-Sorensen","year":"2020","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0235","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1152\/ajpendo.00555.2019","article-title":"Glucagon-dependent suppression of mTORC1 is associated with upregulation of hepatic FGF21 mRNA translation","volume":"319","author":"Welles","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2024.155915_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094996","article-title":"Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism","volume":"9","author":"Cyphert","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/EJE-12-0039","article-title":"Impact of short-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls","volume":"167","author":"Vienberg","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2024.155915_bb0250","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12755","article-title":"Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans","volume":"10","author":"Solomon","year":"2022","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0255","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1152\/ajpendo.00020.2010","article-title":"Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin","volume":"299","author":"Mai","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.metabol.2024.155915_bb0260","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1074\/jbc.M116.762922","article-title":"Glucagon and insulin cooperatively stimulate fibroblast growth factor 21 gene transcription by increasing the expression of activating transcription factor 4","volume":"292","author":"Alonge","year":"2017","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.metabol.2024.155915_bb0265","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2024.155915_bb0270","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2024.155915_bb0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-16-0550","article-title":"Growth differentiation factor 15 increases following oral glucose ingestion: effect of meal composition and obesity","volume":"175","author":"Schernthaner-Reiter","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2265.2011.04139.x","article-title":"Hyperinsulinemia acutely increases serum macrophage inhibitory cytokine-1 concentration in anorexia nervosa and obesity","volume":"76","author":"Karczewska-Kupczewska","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0285","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/db23-0495","article-title":"Fatty acids increase GDF15 and reduce food intake through a GFRAL signaling axis","volume":"73","author":"Wang","year":"2024","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2024.155915_bb0290","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/s42003-022-04242-7","article-title":"Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression","volume":"5","author":"Bomholt","year":"2022","journal-title":"Commun Biol"},{"issue":"5","key":"10.1016\/j.metabol.2024.155915_bb0295","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol"},{"issue":"572","key":"10.1016\/j.metabol.2024.155915_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2024.155915_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155694","article-title":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a multicenter observational study","volume":"148","author":"Valenzuela-Vallejo","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155915_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155237","article-title":"Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity","volume":"133","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.155915_bb0315","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae008","article-title":"Effect of a 6-week carbohydrate-reduced high-protein diet on levels of FGF21 and GDF15 in people with type 2 diabetes","volume":"8","author":"Richter","year":"2024","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.metabol.2024.155915_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111258","article-title":"The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance","volume":"40","author":"Klein","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.metabol.2024.155915_bb0325","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T23:45:29Z","timestamp":1718235929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":65,"alternative-id":["S0026049524001410"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155915","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155915"}}